公开(公告)号：US20240325461A1

公开(公告)日：2024-10-03

申请号：US18619514

申请日：2024-03-28

申请人： Research Development Foundation

发明人： Mirko TRAJKOVSKI ,  Melis ULGEN

IPC分类号： A61K35/741 ,  A61K31/663 ,  A61K35/00 ,  A61K35/747 ,  A61P3/04 ,  A61P3/10 ,  A61P19/10

CPC分类号： A61K35/741 ,  A61K31/663 ,  A61K35/747 ,  A61P3/04 ,  A61P3/10 ,  A61P19/10 ,  A61K2035/115

摘要： Disclosed are combination therapies for the treatment of diseases including obesity and osteoporosis. In some embodiments, an inactivated Parabacteroides goldsteinii is enterically administered to a subject, such as a human patient, in combination with a bisphosphonate such as alendronate to treat the metabolic disease or disorder. Related pharmaceutical and probiotic compositions and methods are provided.

公开(公告)号：US20240238415A1

公开(公告)日：2024-07-18

申请号：US18559261

申请日：2022-05-04

申请人： Baylor College of Medicine

发明人： Brendan LEE

IPC分类号： A61K39/395 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/64 ,  A61P19/08 ,  C07K16/22

CPC分类号： A61K39/3955 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/645 ,  A61P19/08 ,  C07K16/22 ,  C07K2317/21

摘要： The present disclosure provides methods for treating and improving moderate-to-severe osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGFβ).

公开(公告)号：US20240131023A1

公开(公告)日：2024-04-25

申请号：US18460063

申请日：2023-09-01

申请人： Arvinas Operations, Inc.

发明人： LAWRENCE B. Snyder ,  Andrew P. Crew ,  Jing Wang ,  Hanqing Dong

IPC分类号： A61K31/496 ,  A61K31/167 ,  A61K31/277 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/57 ,  A61K31/661 ,  A61K31/663 ,  A61K31/675 ,  A61K38/09 ,  A61K47/54 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/10

CPC分类号： A61K31/496 ,  A61K31/167 ,  A61K31/277 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/57 ,  A61K31/661 ,  A61K31/663 ,  A61K31/675 ,  A61K38/09 ,  A61K47/545 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/10

摘要： This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

公开(公告)号：US11903954B2

公开(公告)日：2024-02-20

申请号：US17879267

申请日：2022-08-02

申请人： Applaud Medical, Inc.

发明人： Daniel J. Laser ,  Alice Luong ,  Robert G. Miotke

IPC分类号： A61K31/685 ,  A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A61K41/00 ,  A61K47/06 ,  A61K47/26 ,  A61K47/32 ,  A61K47/54 ,  A61K47/60 ,  A61K47/69 ,  A61K31/663 ,  A61P13/04 ,  C07F9/38 ,  C07F9/40

CPC分类号： A61K31/685 ,  A61K9/0034 ,  A61K9/167 ,  A61K9/5015 ,  A61K9/5089 ,  A61K41/0028 ,  A61K47/06 ,  A61K47/26 ,  A61K47/32 ,  A61K47/544 ,  A61K47/60 ,  A61K47/6925 ,  A61P13/04 ,  C07F9/3873 ,  C07F9/405 ,  A61K31/663

摘要： The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

公开(公告)号：US11872311B2

公开(公告)日：2024-01-16

申请号：US16800855

申请日：2020-02-25

申请人： The University of North Carolina at Chapel Hill

发明人： Wenbin Lin ,  Demin Liu ,  Joseph Della Rocca ,  Stephanie Kramer ,  Christopher Y. Poon

IPC分类号： A61K47/69 ,  A61K9/14 ,  A61K9/00 ,  A61K9/51 ,  A61P19/10 ,  A61P19/08 ,  A61K31/663 ,  A61K49/00 ,  A61K9/127 ,  A61K47/54 ,  A61P35/00 ,  A61K31/675 ,  A61K51/12

CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/5115 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/663 ,  A61K31/675 ,  A61K47/548 ,  A61K47/6925 ,  A61K47/6929 ,  A61K49/00 ,  A61K51/1244 ,  A61P19/08 ,  A61P19/10 ,  A61P35/00

摘要： Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

公开(公告)号：US20230381209A1

公开(公告)日：2023-11-30

申请号：US18169537

申请日：2023-02-15

申请人： INBIOMOTION S.L.

发明人： Walter Martin GREGORY ,  Juan Carlos TERCERO ,  Roger GOMIS ,  Robert E. COLEMAN

IPC分类号： A61K31/663 ,  A61P35/04 ,  A61K9/00 ,  A61K31/47 ,  C07K16/28 ,  C12Q1/6841 ,  C12Q1/686 ,  C12Q1/6874 ,  C12Q1/6886

CPC分类号： A61K31/663 ,  A61P35/04 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/47 ,  C07K16/2878 ,  C12Q1/6841 ,  C12Q1/686 ,  C12Q1/6874 ,  C12Q1/6886 ,  C12Q2563/107 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/118

摘要： The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

公开(公告)号：US20230285275A1

公开(公告)日：2023-09-14

申请号：US17311010

申请日：2019-12-05

申请人： MEDIFAB CO., LTD.

发明人： Mi Sun CHA ,  Jae Hyup LEE

IPC分类号： A61K9/00 ,  A61P19/00 ,  A61K38/18 ,  A61K38/30 ,  A61K38/40 ,  A61K31/663 ,  A61K9/06

CPC分类号： A61K9/0024 ,  A61P19/00 ,  A61K38/1875 ,  A61K38/1858 ,  A61K38/1841 ,  A61K38/1825 ,  A61K38/30 ,  A61K38/40 ,  A61K31/663 ,  A61K9/06

摘要： The present disclosure relates to: a biocompatible structure comprising a hollow cage, the biocompatible structure comprising, in a surface thereof, one or more open chambers that are recessed inward and hold a biologically active substance; and a method of manufacturing the same. A biocompatible structure according to one aspect comprises a mixed solution of a hydrogel and a biologically active substance in a chamber so that an osteogenesis-promoting substance is released continuously over a long period of time while having initial release stability, and thus osteogenesis at bone defect sites may be improved.

公开(公告)号：US11654153B2

公开(公告)日：2023-05-23

申请号：US16766043

申请日：2018-11-21

申请人： INBIOMOTION S.L.

发明人： Walter Martin Gregory ,  Juan Carlos Tercero ,  Robert E. Coleman ,  Roger Gomis

IPC分类号： A61K31/675 ,  A61P35/04 ,  A61K31/663 ,  A61K45/06 ,  C07K16/28 ,  C12Q1/6886

CPC分类号： A61K31/675 ,  A61K31/663 ,  A61K45/06 ,  A61P35/04 ,  C07K16/2875 ,  C12Q1/6886 ,  C12Q2600/158

摘要： The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

公开(公告)号：US11654152B2

公开(公告)日：2023-05-23

申请号：US16452910

申请日：2019-06-26

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/675 ,  A61K9/28 ,  A61K9/20 ,  A61K9/00 ,  A61K47/12 ,  A61K45/06 ,  C07F9/6506 ,  A61K31/663

CPC分类号： A61K31/675 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2004 ,  A61K9/28 ,  A61K31/663 ,  A61K45/06 ,  A61K47/12 ,  C07F9/6506 ,  A61K9/0095

摘要： Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

公开(公告)号：US20190240245A1

公开(公告)日：2019-08-08

申请号：US16318852

申请日：2017-05-05

申请人： OSTEROS BIOMEDICA LTD.

发明人： Ekaterina Alekseevna IVANOVA ,  Alexander KARPEISKY ,  Shawn P. ZINNEN ,  Lisa Lynn CARALLI ,  Rina Diana FONG

IPC分类号： A61K31/7068 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K47/26 ,  A61P35/00

CPC分类号： A61K31/7068 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/663 ,  A61K47/02 ,  A61K47/26 ,  A61P19/00 ,  A61P35/00

摘要： This invention relates to oncology, and specifically to a novel medicinal drug and a method for treating bone lesions caused by malignant neoplasms. A medicinal drug that represents a lyophilisate for solution for parenteral administration, including the following components: pharmaceutically acceptable salt of the divalent metal and 1-((((((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy))(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethylphosphonic acid or pharmaceutically acceptable salt hereof with a molar ratio of the components ranging from 1:1 to 20:1 is proposed for this purpose. The treatment method includes the drug solution administration according to the invention in the form of intravenous drop infusions in a dose ranging from 0.01 to 5 mg/kg of the active component per 1 kg of the patient's weight in the form of intravenous drop infusions. The treatment with the medicinal drug according to the invention allows to reduce the metabolic activity of bone lesions caused by malignant tumours up to 100%.